Research programme: bicyclic p38 MAP kinase inhibitors - GlaxoSmithKlineAlternative Names: Bicyclic p38 MAP kinase inhibitors research programme - GlaxoSmithKline
Latest Information Update: 17 Jan 2008
At a glance
- Originator GlaxoSmithKline
- Mechanism of Action P38 mitogen-activated protein kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Rheumatoid arthritis
Most Recent Events
- 07 Sep 2004 Preclinical trials in Rheumatoid arthritis in United Kingdom (unspecified route)